AOD 9604 vs tesamorelin is a comparison with real differences
The names get paired in searches about belly fat. I understand why, but the family resemblance tells you less than the human research does.
Why compare them at all?
AOD-9604 is an altered piece of growth hormone. Tesamorelin copies a different hormone that tells the pituitary, a hormone-releasing gland, to release growth hormone. That puts them near the same biological system, with different jobs.
I find it helps to separate the idea from the result. A mechanism explains what researchers hoped to do. A human trial tests what actually happened in a particular group. Sharing part of an explanation doesn't mean two compounds share the same evidence.
Which has evidence for deep belly fat?
Tesamorelin has human evidence for visceral fat in adults with HIV-associated lipodystrophy, a change in fat distribution. Visceral fat sits around abdominal organs. Its approved use is limited to that setting.
AOD-9604's human programme didn't establish the intended weight-loss benefit. Those findings don't support a general promise of spot fat removal from either compound.
Does that make one safer?
I wouldn't decide that from a weight or fat result. Tesamorelin's label has specific warnings about IGF-1, a growth factor, as well as blood-sugar problems and fluid retention. AOD-9604's human tolerability findings don't settle long-term risks or safety by a different route.
A less complete safety picture isn't a cleaner bill of health. I want the warnings and the unanswered questions together, even if that makes a quick comparison less satisfying. Neither a familiar name nor an encouraging headline replaces individual medical review.
Would combining them fill the gaps?
Separate findings don't demonstrate that a combined treatment is safe or effective. AOD-9604's uncertain benefit doesn't become established by adding tesamorelin. Tesamorelin's evidence in adults with HIV doesn't automatically extend to other people either.
The exact preparation matters as well. Research-labelled material isn't interchangeable with an approved tesamorelin product. AOD-9604 has no FDA-approved medical use. A chemical name doesn't establish quality, approval or suitability for the person reading it.
Where do semaglutide and retatrutide fit?
Semaglutide has approved products and human weight-loss evidence. Retatrutide targets three hormone receptors and remains investigational. They add different questions about appetite and metabolism; they don't prove that a multi-compound plan works.
What would I want explained?
Which problem is the proposed treatment meant to address? Which people were studied? What would be monitored, and what would count as a reason to stop? I find those questions more useful than asking which peptide wins.
The separate AOD-9604 and tesamorelin pages leave more room for the safety details. The comparison adds the other compounds without suggesting that they belong in a stack. This is reading for a conversation, not a medicine or dose chosen for you.